Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Tens of thousands of Kaiser Permanente workers in California and Hawaii have gone on strike, demanding safer staffing levels ...

Insurers are cutting coverage for costly GLP-1 weight loss drugs, sparking backlash from advocates who say they're vital for ...

DUOS, a technology-enabled service provider, has raised $130 million to expand its platform to more health plans across the country, it announced on Thursday. The Minneapolis-based company supports ...

Healthcare has been moving steadily out of the clinic and into the home. McKinsey estimates that as much as $265 billion in care (nearly a quarter of all Medicare spending) could shift from facilities ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

CertifyOS, a provider data intelligence company, has launched a new platform to help payers manage provider data in their network, the company announced last week. New York City-based CertifyOS serves ...